{"id":"W4307230056","doi":"10.1158/1078-0432.ccr-22-2235","title":"Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":227,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston; Novartis Pharmaceuticals UK Limited; University of Texas MD Anderson Cancer Center; F. Hoffmann-La Roche; Genentech; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Adverse effect; Sting; Internal medicine; Pharmacodynamics; Gastroenterology; Agonist; Refractory (planetary science); Pharmacokinetics; Pharmacology; Oncology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00442124,0.000164321,0.0005365401,0.0001842607,0.000689566,0.00006101007,0.0009663473,0.00006705501,0.0007545086],"category_scores_gemma":[0.001765137,0.0001195069,0.00004306583,0.0004938142,0.0007797742,0.0001930493,0.001734136,0.001025105,0.00001293267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000230639,"about_ca_system_score_gemma":0.0006513213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189723,"about_ca_topic_score_gemma":0.001080905,"domain_scores_codex":[0.9923269,0.005434053,0.0009903479,0.000534302,0.0002093994,0.0005050161],"domain_scores_gemma":[0.997512,0.001439895,0.000253677,0.0005185065,0.0002266982,0.00004926927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2345929,0.1018232,0.09652131,0.0004457935,0.0009217389,0.0003539421,0.01319241,0.00008071185,0.3228215,0.0006898534,0.006181143,0.2223756],"study_design_scores_gemma":[0.3452917,0.1671835,0.2207098,0.001551202,0.0002664381,0.0001713337,0.1073831,0.001823087,0.1199513,0.0005735914,0.03350009,0.001594822],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952947,0.001573244,0.000001320159,0.0003652514,0.0007456814,0.001807131,0.0001001637,0.00001404045,0.00009850397],"genre_scores_gemma":[0.9967492,0.0001492684,0.00001828977,0.0001336074,0.00001901624,0.0005175093,0.00002713748,0.0000261794,0.002359812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2207808,"threshold_uncertainty_score":0.826134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2811211172679662,"score_gpt":0.5536109955576296,"score_spread":0.2724898782896634,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}